Company news

CNS Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

CNS Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

November 13, 2022

CNS Pharmaceuticals Announces Dosing of First Patient in Europe/France in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM

November 1, 2022

CNS Pharmaceuticals to Participate in The American Brain Tumor Association's Breakthrough (ABTA) for Brain Tumors® 5K (BT5K) Run

October 9, 2022

CNS Pharmaceuticals Announces Activation of First Clinical Trial Sites in Europe for Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM

September 27, 2022

CNS Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

August 14, 2022

CNS Pharmaceuticals Urges Shareholders to Vote in Favor of Proxy Proposals for the Upcoming Annual Meeting of Shareholders on July 27, 2022

July 24, 2022

CNS Pharmaceuticals Receives Approval from U.S. FDA for Protocol Amendment to Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM

June 22, 2022

CNS Pharmaceuticals Announces Presentation of Ongoing Potentially Pivotal Berubicin Clinical Trial Design at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting

June 7, 2022

CNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting

May 17, 2022

CNS Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

May 15, 2022

CNS Pharmaceuticals Receives Approval from Ethics Committee and Competent Authority in Spain for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)

April 27, 2022

CNS Pharmaceuticals Receives Approval from France Ethics Committee and Competent Authority for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)

April 5, 2022

CNS Pharmaceuticals Receives Approval from Competent Authority of Switzerland for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)

April 4, 2022

CNS Pharmaceuticals Reports Full Year 2021 Financial Results and Provides Corporate Update

March 2, 2022

CNS Pharmaceuticals Announces Closing of $11.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

January 9, 2022

CNS Pharmaceuticals Announces $11.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

January 5, 2022

CNS Pharmaceuticals Receives Approval from Switzerland Ethics Committee for its Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)

December 1, 2021

CNS Pharmaceuticals Doses First Group of Patients with Berubicin, an FDA-Designated Fast Track Drug Candidate, in the Potentially Pivotal Study for the Treatment of Glioblastoma Multiforme (GBM)

September 29, 2021

CNS Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Outlook

August 12, 2021

CNS Pharmaceuticals Continues to Execute on Corporate, Clinical and Regulatory Strategies to Drive Berubicin Towards Commercialization for the Treatment of GBM

June 30, 2021

FDA Grants Fast Track Designation to CNS Pharmaceuticals for Berubicin for the Treatment of Recurrent Glioblastoma Multiforme

June 28, 2021

CNS Pharmaceuticals Announces Inclusion in the Russell 2000® Index

June 16, 2021

CNS Pharmaceuticals Commences Patient Enrollment in Potentially Pivotal Study of Berubicin

May 18, 2021

CNS Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Outlook

May 13, 2021

CNS Pharmaceuticals Berubicin Trial is On Schedule to Commence in March 2021

February 24, 2021

CNS Pharmaceuticals to Present at the H.C. Wainwright BioConnect 2021 Conference

January 6, 2021

CNS Pharmaceuticals Announces Pricing of $10.0 Million Public Offering

December 22, 2020

CNS Pharmaceuticals Call to Discuss FDA IND Approval and Phase 2 Trial for Berubicin Today at 8: 30am ET

December 17, 2020

CNS Pharmaceuticals Announces FDA Approval of IND Application for its Brain Cancer Drug Candidate Berubicin

December 16, 2020

CNS Pharmaceuticals Announces Call to Discuss FDA IND Approval and Phase 2 Trial for Berubicin

December 16, 2020

CNS Pharmaceuticals Announces FDA Filing of IND for its Brain Cancer Drug Berubicin

November 16, 2020

CNS Pharmaceuticals to Discuss Phase 2 Clinical Trial Design to be Submitted for FDA Review in Webcast at 4: 30 PM ET Today

November 11, 2020

CNS Pharmaceuticals Announces Adaptive Trial Design For Berubicin Phase 2 Clinical Trial To Be Submitted for FDA Review

November 8, 2020

CNS Pharmaceuticals Completes Manufacturing of Berubicin for Phase 2 Clinical Trial

October 28, 2020

CNS Pharmaceuticals Completes U.S. Manufacturing of Berubicin for Phase 2 Clinical Trial

October 19, 2020

CNS Pharmaceuticals Begins Manufacturing of Berubicin in Europe

October 8, 2020

CNS Pharmaceuticals Achieves Critical Manufacturing Milestone

September 30, 2020

CNS Pharmaceuticals and Image Analysis Group Partner to Further the Development of Berubicin

September 23, 2020

CNS Pharmaceuticals to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

September 16, 2020

CNS Pharmaceuticals Announces US Drug Manufacturing Milestones

September 2, 2020

CNS Pharmaceuticals Announces Appointment of Dr. Patrick Wen, Director of Center for Neuro-Oncology at Dana-Farber Cancer Institute, to Science Advisory Board

August 26, 2020

CNS Provides FDA Update on IND Filing

August 24, 2020

CNS Pharmaceuticals Engages CRO For Phase 2 Berubicin Clinical Trials

August 19, 2020

CNS Pharmaceuticals to Provide Second Quarter 2020 Business Update on Thursday, August 13, 2020

August 10, 2020

CNS Pharmaceuticals Completes Drug Product Manufacturing Strategy for Berubicin

July 14, 2020

CNS Pharmaceuticals Completes Active Ingredient Shipments to Manufacturers

July 7, 2020

CNS Pharmaceuticals Engages Berry Consultants to Advise Phase 2 Trial Design

June 29, 2020

CNS Announces the FDA has Granted Orphan Drug Designation for Brain Cancer Drug Berubicin

June 10, 2020

CNS Announces Highlights from Annual Meeting of Shareholders

June 8, 2020

CNS Pharmaceuticals Announces Sponsored Research Agreement with MD Anderson for Potential Cancer Treatment Technologies

May 27, 2020

← Newer news releases · Older news releases →

Decks

The 5 newest of 24 decks. Every deck is listed under its year.